Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use.

Human pluripotent stem cells show considerable promise for applications in regenerative medicine, including the development of cell replacement paradigms for the treatment of Parkinson's disease. Protocols have been developed to generate authentic midbrain dopamine (mDA) neurons capable of reversing dopamine-related deficits in animal models of Parkinson's disease. However, the generation of mDA neurons at clinical scale suitable for human application remains an important challenge. Here, we present an mDA neuron derivation protocol based on a two-step WNT signaling activation strategy that improves expression of midbrain markers, such as Engrailed-1 (EN1), while minimizing expression of contaminating posterior (hindbrain) and anterior (diencephalic) lineage markers. The resulting neurons exhibit molecular, biochemical, and electrophysiological properties of mDA neurons. Cryopreserved mDA neuron precursors can be successfully transplanted into 6-hydroxydopamine (6OHDA) lesioned rats to induce recovery of amphetamine-induced rotation behavior. The protocol presented here is the basis for clinical-grade mDA neuron production and preclinical safety and efficacy studies.
Competing Interests: Declaration of Interests L.S. is a scientific co-founder and consultant, and V.T. is a founding investigator and consultant, of Bluerock Therapeutics, Inc. M.T. and S.I. are employed by BlueRock Therapeutics, Inc. L.S., S.K., S.I., and M.T. are inventors of a patent WO2016196661A1 filed by Memorial Sloan Kettering Cancer Center on the methods described in this study. All other authors declare no competing interests.
(Copyright © 2021 Elsevier Inc. All rights reserved.)